Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptomic analysis of KMT5A-knockout healthy volunteer peripheral blood CD8+ T cells under activated conditions

ABSTRACT: This study aims to investigate the role of Lysine Methyltransferase 5A (KMT5A, also known as SETD8) in CD8+ T cell biology. CD8+ T cells were isolated from healthy volunteer PBMCs using magnetic bead-based negative selection. Isolated cells were subjected to CRISPR-Cas9 mediated gene editing targeting KMT5A (KMT5A-KO group) or a non-targeting control guide RNA (control group, CTRL) via ribonucleoprotein (RNP) complex electroporation. Cells were harvested at 72 hours post-electroporation for RNA extraction. RNA sequencing (RNA-seq) libraries were constructed using the Illumina TruSeq Stranded mRNA kit and sequenced on an Illumina platform to generate paired-end reads. Transcriptome profiles of KMT5A-KO CD8+ T cells were compared to those of CTRL cells to identify differentially expressed genes (DEGs) and elucidate potential pathways regulated by KMT5A in this cell type.

ORGANISM(S): Homo sapiens

PROVIDER: GSE304753 | GEO | 2025/12/02

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Transcriptomic analysis of KMT5A-knockout healthy volunteer peripheral blood CD8+ T cells under activated conditions

Project description:Transcriptomic analysis of KMT5A-knockout healthy volunteer peripheral blood CD8+ T cells under activated conditions

| PRJNA1302454 | ENA

Identification of KMT5A regulated genes in prostate cancer

Project description:The methyltransferase, KMT5A, is suggested as an oncogene in prostate cancer but the mechanisms underlying its oncogenic properties are poorly understood. This study uncovers genes and cellular pathways which are regulated by KMT5A in LNCaP-AI cells, a model of androgen independence.

2023-05-26 | GSE233350 | GEO

KMT5A-Mediated Methylation of IRF3 Promotes Tumor Progression through Immune Suppression

Project description:Lysine methylation is a critical post-translational modification (PTM) involved in diverse physiological and pathological processes. Interferon regulatory factor 3 (IRF3) plays a pivotal role in antitumor immunity; however, the regulatory mechanisms and functional impact of IRF3 methylation within the tumor microenvironment remain incompletely understood. This study demonstrates that monomethylation of IRF3 at lysine 193 (K193) suppresses its phosphorylation-dependent activation. Mass spectrometry-based protein interactome analysis identified lysine methyltransferase 5A (KMT5A) as the key enzyme responsible for IRF3 K193 monomethylation. In colorectal cancer (CRC), aberrantly high expression of KMT5A impaired in vivo antitumor immune responses. Mechanistically, KMT5A catalyzes IRF3 monomethylation at K193, which impedes IRF3 phosphorylation and subsequent activation, thereby suppressing the production of type I interferons (IFN-I). Collectively, these findings elucidate KMT5A-mediated IRF3 K193 methylation as a critical regulatory axis promoting tumor immune evasion and progression. Furthermore, IRF3 K193 methylation represents a promising therapeutic target for CRC intervention.

2025-12-03 | GSE312287 | GEO

RNA-Seq from SCs after exercise

Project description:RNA seq of Freshly isolated satellite cells from wild type mice after volunteer exercise (VE), endurance exercise (EE) and non-exercise Ctrl (NE)

2025-05-04 | GSE230680 | GEO

Histone lysine methyltransferase Pr-set7/SETD8 promotes neural stem cell reactivation

Project description:The ability of neural stem cells (NSCs) to switch between quiescence and proliferation is crucial for brain development and homeostasis. Increasing evidence suggest that variants of histone lysine methyltransferases including KMT5A are associated with neurodevelopmental disorders. However, the function of KMT5A/Pr-set7/SETD8 in the central nervous system is not well established. Here, we show that Drosophila Pr-Set7 is a novel regulator of NSC reactivation. Loss-of-function of pr-set7 causes a delay in NSC reactivation and loss of H4K20 monomethylation in the brain. Through NSC-specific in vivo profiling, we demonstrate that Pr-set7 binds to the promoter region of cyclin dependent kinase 1 (cdk1) and Wnt pathway transcriptional co-activator earthbound1/jerky (ebd1). Further validation indicates that Pr-set7 is required for the expression of cdk1 and ebd1 in the brain. Similar to Pr-set7, Cdk1 and Ebd1 promote NSC reactivation. Moreover, Cdk1 upregulates the Ebd1 levels in NSCs, while Ebd1 appears to downregulate Cdk1 expression, suggesting a negative feedback regulation. Finally, overexpression of Cdk1 and Ebd1 significantly suppressed NSC reactivation defects observed in pr-set7-depleted brains. Therefore, Pr-set7, the sole H4K20 methyltransferase, promotes NSC reactivation through regulating Wnt signaling and cell-cycle progression. Given the conservation of Pr-set7, our findings may contribute to the understanding of mammalian KMT5A/PR-SET7/SETD8 in NSC proliferation and associated neurodevelopmental disorders.

2021-02-09 | GSE158764 | GEO

Identification of KMT5A regulated genes in prostate cancer

Project description:Identification of KMT5A regulated genes in prostate cancer

| PRJNA975927 | ENA

Inhibition of FBP1 expression by KMT5A through TWIST1 methylation is one of the mechanisms leading to chemoresistance in breast cancer

Project description:Lysine methyltransferase 5A (KMT5A) is the sole mammalian enzyme known to catalyze the monomethylation of histone H4 lysine 20 (H4K20mel) and nonhistone proteins such as p53, which are involved in the occurrence and progression of many cancers. Our study aimed to determine the function of KMT5A in inducing docetaxel resistance in patients with breast carcinoma by evaluating glucose metabolism and the underlying mechanism involved. KMT5A is highly expressed in breast cancer cells; therefore, we examined the upregulation or downregulation of KMT5A-related proteins after KMT5A knockdown in breast cancer cells by TMT proteomics. Through differential protein expression and pathway enrichment analysis, the upregulated key gluconeogenic enzyme fructose-1,6-bisphosphatase 1 (FBP1) was found. Loss of FBP1 expression is closely related to the development and prognosis of various tumors. A dual-luciferase reporter gene assay confirmed that KMT5A inhibited the expression of FBP1 and that overexpression of FBP1 could enhance the chemotherapeutic sensitivity to docetaxel through the suppression of KMT5A expression. The KMT5A inhibitor UNC0379 was used to verify that docetaxel resistance induced by KMT5A through the inhibition of FBP1 depended on the methylase activity of KMT5A. According to previous literature reports and the database interaction network structure, we found that KMT5A acts on the transcription factor TWIST1. Then, we verified that TWSIT1 promoted the expression of FBP1 by using dual-luciferase reporter gene experiments. Depending on its methylase activity, KMT5A can positively regulate glycolysis-mediated chemotherapy resistance by inhibiting the transcription of FBP1 in collaboration with TWIST1. KMT5A affects chemotherapy resistance by regulating the cell cycle, which represents another potential therapeutic target for KMT5A.

2024-04-20 | PXD051634 |

Genome-wide chromatin accessibility profiling of Prdm12-edited CD8+ T cells by ATAC-seq

Project description:This study investigates the impact of Prdm12 knockout on chromatin accessibility in CD8+ T cells. CD8+ T cells were isolated from spleens of OTI:Cas9 transgenic mice (C57BL/6 background) using magnetic bead-based negative selection. Isolated cells were subjected to CRISPR-Cas9 mediated gene editing targeting Prdm12 (Prdm12-KO group) or a non-targeting control guide RNA (Control group) via ribonucleoprotein (RNP) complex electroporation. ATAC-seq was performed to compare genome-wide chromatin accessibility between edited (treatment) and non-edited (control) cells, aiming to identify regulatory regions associated with Prdm12 function.

2025-08-20 | GSE301907 | GEO

The histone methyltransferase Setd8 represses Gata2 expression and regulates erythroid maturation

Project description:The chromatin modifying enzymes that drive the erythroid-specific transcription program are incompletely understood. Setd8 is the sole histone methyltransferase in mammals capable of generating mono-methylated histone H4 lysine 20 (H4K20me1) and is expressed at significantly higher levels in erythroid cells than any other cell- or tissue- type, suggesting that Setd8 has an erythroid-specific function. To test this hypothesis, stable knockdown of Setd8 was established in extensively self-renewing erythroblasts (ESREs), a well-characterized, non-transformed, model of erythroid maturation. Setd8 knockdown impaired erythroid maturation, characterized by a delay in hemoglobin accumulation, larger cell area, persistent kit expression, incomplete nuclear condensation, and lower rates of enucleation than control cells. Setd8 knockdown did not alter ESRE proliferation or viability, or result in accumulation of DNA damage. Global gene expression analyses following Setd8 knockdown suggests that in erythroid cells, Setd8 functions primarily as a repressor and demonstrated high levels of Gata2 expression. Setd8 occupies critical regulatory elements in the Gata2 locus, and knockdown of Setd8 resulted in loss of H4K20me1 and gain of H4 acetylation at the Gata2 1S promoter. Taken together, these results imply that Setd8 is an important regulator of erythroid maturation that works in part through repression of Gata2. RNA-seq was performed of Setd8 knockdown and control cells, both while the cells were proliferating, and after 6 hours of maturation.

2015-04-24 | E-GEOD-62647 | biostudies-arrayexpress

Analysis of differential gene expression in Regorafenib resistant human HCC cells either expressing or lacking Axl

Project description:Human HCC cell line SNU449 and SNU449-Axl-KO were cultured in increasing concentrations of Regorafenib (Rego) to generate resistance. Treatment naive cells (SNU449-ctrl and SNU449-Axl-KO-ctrl) and resistant ones (SNU449-Rego and SNU449-Axl-KO-Rego) were sent for RNA-seq.

2023-09-01 | GSE234647 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data